Adcentrx Therapeutics, a San Diego, CA and Shangai, China-based biotechnology company dedicated to advancing Antibody-Drug Conjugate (ADC) therapeutics for cancer and other life-threatening diseases, closed a $38m Series A+ financing.
The round was led by Eight Roads Ventures, with participation from F-Prime Capital, ABio-X, Delta Capital, Trinity Innovation Fund, and other strategic investors.
The company intends to use the proceeds from the financing to advance its proprietary ADC therapeutic pipeline into the clinic.
Led by Hui Li, Ph.D., Founder and CEO, Adcentrx is a biotechnology company combining the targeting precision of biologics and the disease fighting power of small molecule payloads to advance targeted therapies for improving patient treatment options.
The company’s lead candidate, ADRX-0706, is anticipated to enter a first-in-human Phase 1 clinical trial in the second half of 2023. Adcentrx is developing additional candidates in parallel with the goal of advancing at least one into the clinic each year.
FinSMEs
25/04/2023